Deals
GE Surges After Agreeing to $21.4 Billion Sale of BioPharma Unit
- Culp sees ‘tide beginning to turn’ as deal eases debt concerns
- Troubled giant halts health IPO to focus on pact with Danaher
This article is for subscribers only.
When Larry Culp took command of flailing General Electric Co. late last year, his mandate was simple: be more aggressive.
Fewer than five months later, investors are applauding.